For how we live.
Two WHO-endorsed shots are now available, but a new analysis argues the harder problem is financing them in the lowest-income, highest-burden countries. Nigerian rollout data shows demand outpacing readiness.
As RTS,S reached more than 2 million children in Ghana, Kenya and Malawi, a WHO-coordinated pilot trained about 6,000 health workers to detect and report side-effects that most rollouts assume can already be caught.
Gavi is funding a standing mpox vaccine stockpile, coordinated by the same group that manages emergency supplies for cholera, yellow fever and Ebola, to avoid repeating the 2022 access gap.
HHS Secretary Kennedy held the money over Gavi's use of a mercury-based preservative most safety reviews call harmless in trace amounts. Gavi says it was already phasing the ingredient out.
The FY2027 request would cut global health funding by $4.3 billion and eliminate WHO, PAHO and UNFPA outright. Three weeks later House appropriators proposed a smaller cut.
Global oral cholera vaccine supply has roughly doubled since 2022, enough to release 20 million doses for prevention rather than outbreak response. Nearly all of it comes from a single company.
The final analysis of a 28,130-child trial found roughly 78% efficacy over more than four years, evidence that underpins WHO's push to roll the conjugate vaccine out in endemic countries.